Navigation Links
Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA

A new drug treatment, Revlimid for treatment of myelodysplastic syndrome (MDS), a rare blood disorder has been approved by the Food and Drug Administration (FDA). The approval was announced by Celgene Corp, manufacturer of the drug.//

The exact cause of MDS is not known. However, increased incidence of MDS has been noticed following radiotherapy or chemotherapy. Transfusion of blood and blood products (platelet) is the usual form of treatment. Anti-biotics may also be given to treat the associated infection.

Symptoms of MDS include fatigue, generalized weakness, susceptibility to infections, bleeding tendency and fever. The incidence of MDS is as high as 7000 to 12000 in the United States with a majority of the cases diagnosed in patients over 60 years.

The new drug has been approved by the FDA, owing to its improved performance in clinical trials. The need for a blood transfusion was eliminated in patients treated with Revlimid. Infact, following 3 months of therapy, a majority of the patients became independent of transfusions. This effect was observed for an average of 44 weeks.

The new drug closely resembles another drug, Thalomid, known to cause severe birth defects when administered to the pregnant mother. On account of this structural similarity, a ‘black box’ warning would be issued to prevent fetal exposure to Revlimid.

The drug would further be marketed under a strict adherence to a risk-management strategy, called RevAssist. According to the plan, only registered participants of the program (doctors and pharmacists) would be authorized to prescribe or market Revlimid. This is expected to reduce the probability of fetal exposure to the teratogenic drug.


'"/>




Page: 1

Related medicine news :

1. Revlimid Approved By FDA For Multiple Myeloma
2. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
3. New FDA Approved Drug To Treat Migraine
4. New FDA Approved Drug NATRECOR For Heart Failure Patients
5. New Oral Rinse For Gingivitis Approved By FDA
6. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
7. AIDS Generic Drugs Approved by FDA for Sale in US
8. FDA Approved Nerve-Stimulation Therapy Now Available In New York
9. Pfizer’s Eraxis Approved By The FD
10. Inhalers for Kids Was Approved By the FDA
11. Alcoholism Drug Vivitrol Approved By FDA
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® ... no longer use or need, from clothes to couches to dressers and bicycles. Roadie ... take them to the nearest Goodwill donation center through February 28th. , “January ...
(Date:1/20/2017)... Florida (PRWEB) , ... January 20, 2017 , ... Lice ... head lice cases in families with school-aged children since the holiday season. , ... the holidays with their families, sharing hugs and taking photos, which is the head-to-head ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well ... VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and ... your workout. , After a successful launch in Sweden last year, the next ...
(Date:1/20/2017)... ... 2017 , ... D R Burton Healthcare Products LLC, makers ... in a study indicating superior performance against competitive products in secretion clearance. ... Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter issue ...
(Date:1/20/2017)... ... ... Miracle Man: Against All Odds”: an inspiring affirmation of God’s work. “God's Miracle ... son of Minister Delores Pinnock and a Jamaican native who lives in Kingston and ... up in bed, I felt a pounding headache. It was like a drum beating ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Conference Call and Webcast to Follow Vanda Pharmaceuticals ... release results for the fourth quarter of 2016 on Wednesday, February ... ... 4:30 PM ET on Wednesday, February 15, 2017, during which management ... and other corporate activities. To participate in the conference call, please ...
(Date:1/19/2017)... BOSTON , Jan. 19, 2017  Stealth BioTherapeutics ... therapeutics to treat mitochondrial dysfunction, today announced new additions ... , M.D., as Chief Medical Officer, and Daniel ... Stealth announced that Jim Carr , Pharm.D. has ... "We are pleased to welcome Doug and Daniel ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  Abaxis, Inc. ... manufacturing point-of-care blood analysis instruments and consumables for the ... call to discuss its financial results for the third ... call will be at 4:15 p.m. ET on Thursday, ... for the third quarter fiscal year 2017 after the ...
Breaking Medicine Technology: